atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$1.16 USD
+0.10 (9.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:24 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for atai Life Sciences NV falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 20 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 20 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 126 | 145 | 156 | 104 | 18 |
Income After Depreciation & Amortization | -125 | -145 | -136 | -104 | -18 |
Non-Operating Income | 89 | 10 | -1 | 2 | 0 |
Interest Expense | 3 | 0 | 0 | 0 | 0 |
Pretax Income | -39 | -135 | -137 | -102 | -17 |
Income Taxes | 1 | 6 | -4 | 0 | 0 |
Minority Interest | -4 | -5 | -6 | -9 | -10 |
Investment Gains/Losses | -4 | -16 | -42 | -77 | -7 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -44 | -157 | -174 | -179 | -24 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -40 | -152 | -168 | -170 | -14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -125 | -145 | -136 | -104 | -18 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -125 | -145 | -136 | -104 | -18 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 158.83 | 155.72 | 138.27 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.25 | -0.98 | -1.15 | NA | NA |
Diluted Net EPS (GAAP) | -0.25 | -0.98 | -1.21 | -1.83 | NA |
Fiscal Year end for atai Life Sciences NV falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.27 | 0.00 | 0.02 | 0.09 | 0.17 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.27 | 0.00 | 0.02 | 0.09 | 0.17 |
SG&A, R&D, and Dept/Amort Expenses | 26.01 | 24.09 | 33.58 | 26.92 | 32.04 |
Income After SG&A, R&D, and Dept/Amort Expenses | -25.74 | -24.09 | -33.56 | -26.83 | -31.87 |
Non-Operating Income | -30.65 | -0.91 | 16.94 | 71.37 | 0.86 |
Interest Expense | 0.70 | 0.69 | 0.69 | 0.69 | 0.66 |
Pretax Income | -57.08 | -25.68 | -18.32 | 43.85 | -31.66 |
Income Taxes | 0.02 | 0.00 | 0.43 | 0.24 | 0.19 |
Minority Interest | -0.06 | -0.67 | -0.85 | -0.87 | -0.73 |
Investment Gains/Losses | -0.27 | -1.70 | -0.39 | -0.24 | -1.93 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -57.37 | -27.38 | -19.14 | 43.37 | -33.77 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -57.31 | -26.71 | -18.29 | 44.24 | -33.04 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 160.39 | 158.89 | 158.84 | 177.57 | 155.79 |
Diluted EPS Before Non-Recurring Items | -0.36 | -0.17 | -0.12 | -0.14 | -0.21 |
Diluted Net EPS (GAAP) | -0.36 | -0.17 | -0.08 | 0.25 | -0.21 |